Your browser doesn't support javascript.
loading
[Efficiency and safety of peptide receptor radionuclide therapy in the treatment of metastatic neuroendocrine tumors].
Yao, X C; Zhang, C; Zang, S M; Zhang, P J; Wang, J; Xu, L; Yu, F; Gao, X J; Tang, Q Y; Wang, F.
Afiliación
  • Yao XC; Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
  • Zhang C; Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
  • Zang SM; Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
  • Zhang PJ; Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
  • Wang J; Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
  • Xu L; Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
  • Yu F; Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
  • Gao XJ; Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
  • Tang QY; Institution of Neuroendocrinology, Nanjing Medical University, Nanjing 210000, China.
  • Wang F; Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
Zhonghua Yi Xue Za Zhi ; 102(14): 1034-1038, 2022 Apr 12.
Article en Zh | MEDLINE | ID: mdl-35399024
ABSTRACT
The clinical data of 14 patients with neuroendocrine tumors who received Peptide Receptor Radionuclide Therapy (PRRT) from December 2018 to May 2021 were retrospectively analyzed. Among them, 2 patients demonstrated proprogressive disease, 2 patients had partial response, and 10 patients had stable disease. Grade 1-2 myelosuppression occurred in 5 patients. and 1 patient became grade 3 myelosuppression，which recovered to grade 2 after symptomatic treatment. No grade 2 or higher treatment-related renal toxicity was observed in any of the patients. PRRT is efficacy and no significant side effects for unresectable metastatic neuroendocrine tumors.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tumores Neuroendocrinos Tipo de estudio: Observational_studies Límite: Humans Idioma: Zh Revista: Zhonghua Yi Xue Za Zhi Año: 2022 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Tumores Neuroendocrinos Tipo de estudio: Observational_studies Límite: Humans Idioma: Zh Revista: Zhonghua Yi Xue Za Zhi Año: 2022 Tipo del documento: Article País de afiliación: China